Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Cantor Fitzgerald Reiterates Overweight on Marinus Pharma, Maintains $28 Price Target

Cantor Fitzgerald Reiterates Overweight on Marinus Pharma, Maintains $28 Price Target

Cantor Fitzgerald analyst Charles Duncan reiterates Marinus Pharma (NASDAQ:MRNS) with a Overweight and maintains $28 price target.

March 8, 2023

1 minute read

Cantor Fitzgerald analyst Charles Duncan reiterates Marinus Pharma (NASDAQ:MRNS) with a Overweight and maintains $28 price target.

Piper Sandler Maintains Overweight on YETI Holdings, Lowers Price Target to $48

October 12, 7:17 AM

Piper Sandler analyst Peter Keith maintains YETI Holdings (NYSE:YETI) with a Overweight and lowers the price target from $76 to $48.

September 5, 11:44 AM

America’s Car-Mart Inc (NASDAQ: CRMT) reported

September 7, 5:45 PM

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Pfizer’s (NYSE:PFE) lead drug GBS6…

March 1, 8:51 AM

Barclays analyst Anthony Powell maintains UDR (NYSE:UDR) with a Overweight and raises the price target from $44 to $50.